Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis

Cancer

Volumn 121, Issue 20, 2015, Pages 3649-3658

  Martin, Robert C G ^a,b   Scoggins, Charles R ^a,b   Schreeder, Marshall ^c   Rilling, William S ^d   Laing, Christopher J ^e   Tatum, Clifton M ^f   Kelly, Lawrence R ^f   Garcia Monaco, Ricardo D ^g   Sharma, Vivek R ^a,b   Crocenzi, Todd S ^h   Strasberg, Steven M ⁱ  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^c Clearview Cancer Institute   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e Department of Radiology at Winthrop Interventional Radiology   (United States)

^f Norton Radiology Associates   (United States)

^g HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^h PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

ⁱ USA   (United States)

Author keywords

hepatic artery therapy; irinotecan; liver directed therapy; liver dominant metastatic colorectal cancer; metastatic colon cancer

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ARTICLE; ASCITES; BILE DUCT DILATATION; BILIARY TRACT HEMORRHAGE; CANCER CHEMOTHERAPY; CHOLECYSTITIS; COLORECTAL LIVER METASTASIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG RESPONSE; EMBOLIC PARTICLE; FEMALE; FOLLOW UP; HEART DISEASE; HEPATIC ARTERY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFECTION; LIVER RESECTION; LIVER TOXICITY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; THROMBOCYTOPENIA; VASCULAR DISEASE; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DEVICES; DRUG DELIVERY SYSTEM; DRUG EFFECTS; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; SECONDARY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; FLUOROURACIL; HEPATIC ARTERY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84943584879     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29534     Document Type: Article

References (31)

1. Pulitano C, Bodingbauer M, Aldrighetti L, et al., Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol. 2011; 18: 1380-1388.
2. Brouquet A, Abdalla EK, Kopetz S, et al., High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011; 29: 1083-1090.
3. Schwarz RE, Berlin JD, Lenz HJ, et al., HPB (Oxford). 2013; 15: 106-115.
4. Falcone A, Ricci S, Brunetti I, et al., Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007; 25: 1670-1676.
5. Nordlinger B, Sorbye H, Glimelius B, et al., Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008; 371: 1007-1016.
6. Nakano H, Oussoultzoglou E, Rosso E, et al., Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008; 247: 118-124.
7. Martin RC, Joshi J, Robbins K, et al., Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011; 18: 192-198.
8. Martin RC II, Scoggins CR, Tomalty D, et al., Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg. 2012; 16: 1531-1538.
9. Martin RC, Joshi J, Robbins K, et al., Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol. 2009; 2009: 539795.
10. Martin RC, Robbins K, Tomalty D, et al., Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol. 2009; 7: 80.
11. Vauthey JN, Choti MA, Helton WS,. AHPBA/SSO/SSAT consensus conference on hepatic colorectal metastases: rationale and overview of the conference. January 25, 2006. Ann Surg Oncol. 2006; 13: 1259-1260.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al., New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
13. Soulen MC,. Regional therapy of hepatic malignancies. Curr Treat Options Gastroenterol. 1999; 2: 437-440.
14. Sanz-Altamira PM, Spence LD, Huberman MS, et al., Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum. 1997; 40: 770-775.
15. Chung WS, Park MS, Shin SJ, et al., Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria. AJR Am J Roentgenol. 2012; 199: 809-815.
16. Choi H, Charnsangavej C, Faria SC, et al., Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25: 1753-1759.
17. Soulen MC,. Chemoembolization of hepatic malignancies. Oncology (Williston Park). 1994; 8: 77-84.
18. Kemeny NE, Melendez FD, Capanu M, et al., Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009; 27: 3465-3471.
19. Bavisotto LM, Patel NH, Althaus SJ, et al., Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104). Clin Cancer Res. 1999; 5: 95-109.
20. Venook AP, Warren RS,. Regional chemotherapy approaches for primary and metastatic liver tumors. Surg Oncol Clin N Am. 1996; 5: 411-427.
21. Tellez C, Benson AB III, Lyster MT, et al., Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer. 1998; 82: 1250-1259.
22. Egger ME, Cannon RM, Metzger TL, et al., Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor. J Am Coll Surg. 2013; 216: 845-856.
23. Lencioni R, Llovet JM,. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30: 52-60.
24. Prajapati HJ, Spivey JR, Hanish SI, et al., mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol. 2013; 24: 965-973.
25. Choi J,. Imaging of hepatic metastases. Cancer Control. 2006; 13: 6-12.
26. Lencioni R, Llovet JM, Han G, et al., Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial [abstract]. J Clin Oncol. 2012; 30 (suppl 4): LBA154.
27. Fiorentini G, Aliberti C, Mulazzani L, et al., Chemoembolization in colorectal liver metastases: the rebirth. Anticancer Res. 2014; 34: 575-584.
28. Fiorentini G, Aliberti C, Tilli M, et al., Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012; 32: 1387-1395.
29. Vitola JV, Delbeke D, Meranze SG, et al., Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer. 1996; 78: 2216-2222.
30. Martin RC, Howard J, Tomalty D, et al., Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol. 2010; 33: 960-966.
31. Lencioni R, Aliberti C, de Baere T, et al., Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations. J Vasc Interv Radiol. 2014; 25: 365-369.